Similar articles for PMID: 22214462

Year	Number of Results
2002	1
2003	1
2004	1
2005	4
2006	10
2007	7
2008	12
2009	24
2010	30
2011	31
2012	24
2013	8
2014	7
2015	4
2016	3
2017	4
2018	2
2019	3
2020	4
2021	2
2022	2
2024	0

1

Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.

Ranieri G, Gadaleta-Caldarola G, Goffredo V, Patruno R, Mangia A, Rizzo A, Sciorsci RL, Gadaleta CD. Ranieri G, et al. Curr Med Chem. 2012;19(7):938-44. doi: 10.2174/092986712799320736. Curr Med Chem. 2012. PMID: 22214462 Review.

2

Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.

Strumberg D. Strumberg D. Drugs Today (Barc). 2005 Dec;41(12):773-84. doi: 10.1358/dot.2005.41.12.937959. Drugs Today (Barc). 2005. PMID: 16474853 Review.

3

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Liu L, et al. Cancer Res. 2006 Dec 15;66(24):11851-8. doi: 10.1158/0008-5472.CAN-06-1377. Cancer Res. 2006. PMID: 17178882

4

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

Adnane L, Trail PA, Taylor I, Wilhelm SM. Adnane L, et al. Methods Enzymol. 2006;407:597-612. doi: 10.1016/S0076-6879(05)07047-3. Methods Enzymol. 2006. PMID: 16757355

5

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Keating GM, Santoro A. Keating GM, et al. Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. Drugs. 2009. PMID: 19228077 Review.

6

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. Wilhelm SM, et al. Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443. Cancer Res. 2004. PMID: 15466206

7

Sorafenib.

Hasskarl J. Hasskarl J. Recent Results Cancer Res. 2010;184:61-70. doi: 10.1007/978-3-642-01222-8_5. Recent Results Cancer Res. 2010. PMID: 20072831 Review.

8

Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.

Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J. Gu FM, et al. World J Gastroenterol. 2011 Sep 14;17(34):3922-32. doi: 10.3748/wjg.v17.i34.3922. World J Gastroenterol. 2011. PMID: 22025881 Free PMC article.

9

Sorafenib, a systemic therapy for hepatocellular carcinoma.

Méndez-Sánchez N, Vásquez-Fernández F, Zamora-Valdés D, Uribe M. Méndez-Sánchez N, et al. Ann Hepatol. 2008 Jan-Mar;7(1):46-51. Ann Hepatol. 2008. PMID: 18376365 Free article. Review.

10

Sorafenib in liver cancer.

Woo HY, Heo J. Woo HY, et al. Expert Opin Pharmacother. 2012 May;13(7):1059-67. doi: 10.1517/14656566.2012.679930. Expert Opin Pharmacother. 2012. PMID: 22519770 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

167 results

Results by year